ReviewImmunologic research2025
RNA-based cancer vaccines: mechanisms, clinical progress, and translational challenges.
Review in Immunologic research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review
- Therapeutic melanoma vaccines: Platforms, neoantigen strategies, and emerging combination immunotherapies.Therapeutic advances in vaccines and immunotherapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent advancements in vaccine technology have led to the development of RNA-based vaccines, including mRNA, circular RNA, and self-amplifying mRNA, which have emerged as a promising platform for tumor prevention and treatment. In comparison with conventional antitumor vaccines, such as whole cell, peptide, and DNA vaccines, RNA vaccines possess several advantageous characteristics. They have the capacity to encode multiple antigens, induce robust immune responses, and can be developed more expeditiously. Additionally, RNA vaccines have the potential for scalable manufacturing with acceptable safety profiles in cancer patients. Preliminary investigations, conducted both in preclinical and clinical settings, have yielded encouraging outcomes for RNA vaccines in the context of diverse tumor types. This review delineates the types, advances, and applications of RNA vaccines in antitumor therapy, as well as the challenges associated with their use. Finally, it introduces future technological directions for improving these current vaccine platforms for a wide range of therapeutic uses.
Indexed as
Identifiers
41264102What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.